Arrowpoint Investment Partners (Singapore) Pte. Ltd. Ventyx Biosciences, Inc. Transaction History
Arrowpoint Investment Partners (Singapore) Pte. Ltd.
- $100 Billion
- Q3 2025
A detailed history of Arrowpoint Investment Partners (Singapore) Pte. Ltd. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Arrowpoint Investment Partners (Singapore) Pte. Ltd. holds 26,858 shares of VTYX stock, worth $248,436. This represents 0.08% of its overall portfolio holdings.
Number of Shares
26,858Holding current value
$248,436% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding VTYX
# of Institutions
121Shares Held
48.5MCall Options Held
152KPut Options Held
43.8K-
Black Rock Inc. New York, NY4.77MShares$44.1 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.92MShares$36.3 Million1.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$34.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.21MShares$29.7 Million0.02% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$28.7 Million0.44% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $523M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...